financetom
Business
financetom
/
Business
/
Thomson Reuters Faces 'High Bar' on Valuation Despite Strong Margins, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Thomson Reuters Faces 'High Bar' on Valuation Despite Strong Margins, Morgan Stanley Says
Nov 5, 2025 8:09 AM

10:48 AM EST, 11/05/2025 (MT Newswires) -- Thomson Reuters ( TMSOF ) posted solid Q3 results, beating expectations, but shares eased as the company guided full-year organic growth to the lower end of prior guidance, Morgan Stanley said in a Tuesday note.

Management now expects full-year organic growth at the lower end of the 7%-7.5% range, citing a slower print recovery, government contract cancellations, and softer corporate sales momentum, according to the report.

Legal Professionals posted a record 9% organic growth, while Print declined 4%. The company also raised its 2026 margin expansion target to 100 basis points from 50 basis points and guided free cash flow to $2.1 billion.

Analysts noted that while Thomson Reuters' ( TMSOF ) fundamentals and execution remain strong, its valuation limits near-term upside potential.

The firm maintained an equal weight rating on the stock and lowered its price target to $172 from $187.

Price: 147.92, Change: +1.19, Percent Change: +0.81

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FibroBiologics Gets European Patent for Cancer Treatment Using Modified Fibroblasts
FibroBiologics Gets European Patent for Cancer Treatment Using Modified Fibroblasts
Oct 17, 2024
10:11 AM EDT, 10/16/2024 (MT Newswires) -- FibroBiologics ( FBLG ) said Wednesday it has received a new patent from the European Patent Office for a cancer treatment method that uses modified fibroblasts to deliver anti-cancer agents. The patent covers methods to enhance fibroblasts' ability to target tumors and deliver cancer-fighting agents by leveraging their natural capacity to penetrate tumors...
Looking At Citigroup's Recent Unusual Options Activity
Looking At Citigroup's Recent Unusual Options Activity
Oct 17, 2024
Whales with a lot of money to spend have taken a noticeably bullish stance on Citigroup ( C ). Looking at options history for Citigroup ( C ) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish. From...
Solar panel maker Maxeon says George Guo to succeed Mulligan as CEO
Solar panel maker Maxeon says George Guo to succeed Mulligan as CEO
Oct 17, 2024
Oct 16 (Reuters) - Renewable energy company Maxeon Solar Technologies ( MAXN ) said on Wednesday its chief executive officer Bill Mulligan will retire at the end of January next year, after nearly two years in the role, and will be succeeded by George Guo. Guo, former CEO of TCL Communication, has assumed the role at Maxeon and joined its...
Toyota, Boston Dynamics Launch Partnership for Robotics Research
Toyota, Boston Dynamics Launch Partnership for Robotics Research
Oct 17, 2024
10:08 AM EDT, 10/16/2024 (MT Newswires) -- Toyota's ( TM ) Toyota Research Institute and Boston Dynamics said Wednesday they are launching a partnership to advance robotics research. The partnership, which aims to accelerate the development of humanoid robots, will use Toyota Research Institute's large behavior models and Boston Dynamics' Atlas robot, the companies said. Financial details weren't provided. Price:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved